Abstract
Drug-induced liver injury may cause impairment of liver function and is a leading cause of acute liver failure. Identification of the causative substance in patients receiving several drugs is often difficult in clinical practice. Evaluation of liver biopsies in suspected drug-induced injury is a challenging task that requires close clinico-pathological correlation. Recognizing a characteristic morphological pattern of liver injury may contribute to identification of the causative drug. Flupirtine, a non-opioid analgesic, has been reported to cause liver injury of idiosyncratic type in rare instances. We wished to characterize the histopathological features of flupirtine-induced liver injury, which have not been reported so far. Liver biopsies of five patients with severe liver injury and one explanted liver of a patient with flupirtine-induced acute liver failure that required transplantation were assessed. In addition clinical presentation and course were reviewed and clinical follow up was performed. Extensive perivenular necrosis with associated ceroid pigment-laden macrophages and a mild to moderate lymphocytic infiltrate was a common feature in all cases. Histological extent of liver necrosis corresponded well to serum amino-transferase levels. Accidental reexposure of one patient resulted in a plasma cell rich hepatitis with perivenular necrosis. This study provides evidence that flupirtine can cause substantial liver injury of hepatocellular type. Liver damage is associated with a characteristic morphological picture, the recognition of which will aid in causality assessment of drug-induced liver injury. Clinical and histological features raise the possibility of an immune-mediated toxicity.
Similar content being viewed by others
References
Hoofnagle JH (2004) Drug-induced liver injury network (DILIN). Hepatology 40(4):773. doi:10.1002/hep.20445
Kaplowitz N (2007) Drug-induced liver disease. In: Kaplowitz N, DeLeve LD (eds) Drug-induced liver disease, 2nd edn. Informa Healthcare, New York, pp 1–13
Bell L, Chalasani N (2009) Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 29(04):337–347. doi:10.1055/s-0029-1240002
De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E (2006) Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 24(8):1187–1195. doi:10.1111/j.1365-2036.2006.03117.x
Hussaini SH, O’Brien CS, Despott EJ, Dalton HR (2007) Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 19(1):15–20. doi:10.1097/01.meg.0000250581.77865.68
Kanel GC (2007) Histopathology of drug-induced liver disease. In: Kaplowitz N, DeLeve LD (eds) Drug-induced liver disease, 2nd edn. Informa Healthcare, New York, pp 237–290
Fontana RJ, Seeff LB, Andrade RJ, Bjornsson E, Day CP, Serrano J, Hoofnagle JH (2010) Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 52(2):730–742. doi:10.1002/hep.23696
Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46(11):1323–1330
Kleiner DE (2009) The pathology of drug-induced liver injury. Semin Liver Dis 29(4):364–372. doi:10.1055/s-0029-1240005
Ramachandran R, Kakar S (2009) Histological patterns in drug-induced liver disease. J Clin Pathol 62(6):481–492. doi:10.1136/jcp.2008.058248
MacSween RNM, Burt AD, Portmann BC, Ferrell LD (2007) MacSween’s pathology of the liver, 5th edn. Elsevier, Churchill Livingstone, Philadelphia
Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4(2):315–323
Neuberger J, Williams R (1989) Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 30(4):515–519
Pothmann R, Lobisch M (2000) Acute treatment of episodic childhood tension-type headache with flupirtine and paracetamol — a double-blind crossover-study. Schmerz 14(1):1–4. doi:10.1007/s004820000058
Muller-Schwefe GH, Uberall MA (2007) Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. MMW Fortschr Med 149(43):47
Goodchild CS, Nelson J, Cooke I, Ashby M, Jackson K (2008) Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer. Pain Med 9(7):939–949. doi:10.1111/j.1526-4637.2008.00512.x
Schwabe U, Paffrath D (2009) Arzneiverordnungs—Report 2009: Aktuelle Daten, Kosten. Trends und Kommentare, Springer, Berlin
Klawe C, Maschke M (2009) Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother 10(9):1495–1500. doi:10.1517/14656560902988528
Hufschmidt A, Krisch A, Peschen I (2009) A girl with headache, confusion and green urine. J Neurol 256(7):1169–1170. doi:10.1007/s00415-009-5061-2
Hlavica P, Niebch G (1985) Pharmacokinetics and biotransformation of the analgesic flupirtine in humans. Arzneimittelforschung 35(1):67–74
Friedel HA, Fitton A (1993) Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 45(4):548–569
Li C, Ni J, Wang Z, Li M, Gasparic M, Terhaag B, Uberall MA (2008) Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 24(12):3523–3530. doi:10.1185/03007990802579769
Powell-Jackson P, Williams R (1985) Use of flupirtine maleate as an analgesic in patients with liver disease. Br J Clin Pract 39(2):63–66
Arzneimittelkommission der deutschen Ärzteschaft (2007) Mitteilungen: “Aus der UAW-Datenbank” Leberschäden unter Flupirtin. http://www.aerzteblatt.de/v4/archiv/artikel.asp?src=heft&id=57646. Accessed 11.04.2011
Klein F, Glanemann M, Rudolph B, Seehofer D, Neuhaus P (2011) Flupirtine induced hepatic failure requiring orthotopic liver transplantation. Experimental and Clinical Transplantation, in press
Wills EJ, Walton B (1978) A morphologic study of unexplained hepatitis following halothane anesthesia. Am J Pathol 91(1):11–32
Klion FM, Schaffner F, Popper H (1969) Hepatitis after exposure to halothane. Ann Intern Med 71(3):467–477
Benjamin SB, Goodman ZD, Ishak KG, Zimmerman HJ, Irey NS (1985) The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases. Hepatology 5(6):1163–1171
Banks AT, Zimmerman HJ, Ishak KG, Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22(3):820–827
Scully LJ, Clarke D, Barr RJ (1993) Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 38(4):744–751
Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK (1998) Adverse drug reactions. BMJ 316(7140):1295–1298
Navarro VJ, Senior JR (2006) Drug-related hepatotoxicity. N Engl J Med 354(7):731–739. doi:10.1056/NEJMra052270
Conflicts of interest
The authors have no conflicts to declare.
Author information
Authors and Affiliations
Corresponding author
Additional information
Florian Puls and Clemens Agne contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 3.01 MB)
Rights and permissions
About this article
Cite this article
Puls, F., Agne, C., Klein, F. et al. Pathology of flupirtine-induced liver injury:. Virchows Arch 458, 709–716 (2011). https://doi.org/10.1007/s00428-011-1087-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-011-1087-9